Navigation Links
Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II,trial of Cloretazine (VNP40101M) in Patients with Relapsed or,Refractory Small Cell Lung Cancer

. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. In preclinical studies, Vion is also evaluating VNP40541, a hypoxia-selective compound, and hydrazone compounds. The Company also is seeking development partners for TAPET(R), its modified Salmonella vector used to deliver anticancer agents directly to tumors. For additional information on Vion and its product development programs, visit the Company's Internet web site at www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion's potential inability to obtain regulatory approval for its products, delayed or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies or clinical trials are not predictive of safety and efficacy results in later clinical trials, the need for additional research and testing, the potential inability to secure external sources of funding to continue operations, the inability to access capital and funding on favorable terms, continued operating losses and the inability to continue operations as a result, and a variety of other risks set forth from time to time in Vion's filings with the Securities and Exchange Commission, including but not limited to the risks attendant to the forward-looking statements included under Item 1A, "Risk Factors" in Vion's Annual Report on Form 10-K for the year ended December 31, 2006. In particular, there can be no assurance as to the results of any of the Company's clinical trials, that any of these trials will continue to full accrual, or that any of these trials will not be discontinued, modified, delayed or ceased altogether. Except in special circumstances in which a duty to update arises un
'"/>




Page: 1 2 3 4

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:8/28/2015)... PITTSBURGH , Aug. 28, 2015 ... announced that its shareholders have approved Mylan,s proposed ... ; TASE) and the related issuance of Mylan ... general meeting of shareholders held today. The transaction ... the extraordinary general meeting. In addition, the transaction ...
(Date:8/28/2015)... -- The report "Eubiotics Market by Type (Probiotics, Prebiotics, Organic ... & by Region ( North America , ... Rest of the World) - Global Trends and Forecast to ... valued at USD 4.62 Billion in 2014 and is projected ... of 7.4% from 2015 to 2020. Browse ...
(Date:8/28/2015)... ANDOVER, Massachusetts and LONDON , ... driven approach seamlessly ... health continuum improving outcomes and ... Philips  (NYSE: PHG AEX: PHIA) today announced its presence ... its latest cardiology solutions, including Heart Model A.I. , EchoNavigator ...
Breaking Medicine Technology:Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 3Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 4Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 6Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 7Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 8Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 9Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 2Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 3Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 4
... DIEGO, Jan. 9, 2012   Aethlon Medical, Inc. ... to address infectious disease and cancer, announced that an ... CEO, James A. Joyce, at the Biotech Showcase™ 2012, ... (Photo:  http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b ) ...
... or the Company) (NASDAQ: HOLX ), a ... medical imaging systems and surgical products dedicated to serving ... Inc.,s (Conceptus) request for an injunction barring future sales ... denied and that no royalty will be due to ...
Cached Medicine Technology:Aethlon Medical Discloses Availability of the Biotech Showcase™ 2012 Presentation 2Hologic Announces Denial of Conceptus' Request for Injunction in Patent Infringement Suit 2Hologic Announces Denial of Conceptus' Request for Injunction in Patent Infringement Suit 3
(Date:8/28/2015)... ... August 28, 2015 , ... Joining a ... Memorial Hospital recently transitioned management companies to partner with Wound Care Advantage (WCA) ... outpatient wound center. , Transitioning wound care management providers can be a ...
(Date:8/28/2015)... ... August 28, 2015 , ... Approximately 2,000 United Methodists ... celebrate children helping children, a thank you to the many creative and generous ... to the United Methodist initiative to end malaria deaths. , The Columbus Zoo ...
(Date:8/28/2015)... ... , ... An article published August 19th by the LA Times ... to open a pizzeria in Westchester. Mr. LaRocco was aware from opening prior pizza ... the current process, having already gone on for over a year, is taking much ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... For Dallas, ... is taking part with their subsidiary USPI Tenet Health. , The American Heart Association ... heart disease and stroke. They believe that together, a difference can be made. Walkers ...
(Date:8/28/2015)... Baltimore, MD (PRWEB) , ... August 28, 2015 , ... ... reduction system from Merz, received FDA clearance for results that last for two ... clearance is exciting news for patients who are looking for a long-lasting, effective solution ...
Breaking Medicine News(10 mins):Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 3Health News:Article on Building Approval Process for LA Business Highlights the Need for a Bridge Between Businesses and City Officials, says Fire Protection Group Inc. 2Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3
... 1, WASHINGTON, May 1 U.S. Paralympian April ... on the track. In September, she,will travel to Beijing ... favored to medal in the 100- and 200-meter dashes. ... well what working,Americans need to do to keep their ...
... notes, "We make,decisions for the right reasons and then we ... the right time, by the right people, and at the,right ... Management has now grown so much that an increasingly,sophisticated system ... and strategic at its core -- but that is fraught ...
... ... HILLS, Ill. and CORPUS CHRISTI, Texas, May 1 ... from Texas,A&M-Corpus Christi,s Kinesiology Department demonstrated the correlation,between improved ... improvement in the hitting performance of,Islander baseball players after ...
... Texas Cardiac Arrhythmia Recruits and Hires Dr. Andrea ... Executive Medical Director of the Texas Cardiac Arrhythmia,Institute ... May 1 St. David,s HealthCare,along with Texas ... Cardiac Arrhythmia Institute (TCAI) at St. David,s Medical ...
... N.C., May 1 The Oregon State,Supreme Court ... statewide class,action in which plaintiff sought to make ... for medical monitoring of all Oregon,cigarette smokers., ... of the complaint and,the intermediate appellate court,s unanimous ...
... hinder a protein called IGF-1 not entirely successful, studies ... idea that prostate cancer can be treated successfully just ... growth factor (IGF-1) has been undermined by two new ... by a number of drug companies and academic researchers, ...
Cached Medicine News:Health News:U.S. Paralympian April Holmes Teams With LIFE Foundation to Encourage Americans to Assess Their Disability Insurance Needs This May 2Health News:U.S. Paralympian April Holmes Teams With LIFE Foundation to Encourage Americans to Assess Their Disability Insurance Needs This May 3Health News:U.S. Paralympian April Holmes Teams With LIFE Foundation to Encourage Americans to Assess Their Disability Insurance Needs This May 4Health News:Best Practices in Designing Effective Brand Teams 2Health News:Study by Texas A&M University-Corpus Christi Confirms Training With Vision Software Enhances Hitting Skills 2Health News:St. David's HealthCare and Texas Cardiac Arrhythmia Announce International Center For Training, Research and Treatment of Heart Rhythm Disorders 2Health News:St. David's HealthCare and Texas Cardiac Arrhythmia Announce International Center For Training, Research and Treatment of Heart Rhythm Disorders 3Health News:St. David's HealthCare and Texas Cardiac Arrhythmia Announce International Center For Training, Research and Treatment of Heart Rhythm Disorders 4Health News:Complications Found in Proposed Prostate Cancer Treatment 2
For the qualitative detection of group A streptococcal antigen from throat swabs....
For the qualitative detection of human Chorionic Gonadotrophin (hCG) in urine specimens...
For the qualitative detection of human Chorionic Gonadotrophin (HCG) in urine or urine and serum specimens...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
Medicine Products: